Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday on FDA Approval of First siRNA Therapy for FCS

Stock Track12-01

Arrowhead Pharmaceuticals (ARWR) saw its stock price surge 5.08% during intraday trading on Monday, reflecting strong investor optimism following a significant regulatory milestone.

The rally was driven by the U.S. FDA's approval of REDEMPLO (plozasiran), Arrowhead's first siRNA therapy for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This approval marks a pivotal transition for the company into a commercial-stage entity, with REDEMPLO offering a quarterly self-administered treatment option at home.

The FDA nod not only validates Arrowhead's RNAi platform but also opens new revenue streams, supported by recent licensing and collaboration deals, including a global agreement with Novartis worth up to $2 billion. This development has reshaped the company's investment narrative, shifting focus from partnership-dependent revenue to a more balanced business model.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194159638?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194159638","market":"us","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday on FDA Approval of First siRNA Therapy for FCS","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals (ARWR) saw its stock price surge 5.08% during intraday trading on Monday, reflecting strong investor optimism following a significant regulatory milestone.</p><p>The rally was driven by the U.S. FDA's approval of REDEMPLO (plozasiran), Arrowhead's first siRNA therapy for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This approval marks a pivotal transition for the company into a commercial-stage entity, with REDEMPLO offering a quarterly self-administered treatment option at home.</p><p>The FDA nod not only validates Arrowhead's RNAi platform but also opens new revenue streams, supported by recent licensing and collaboration deals, including a global agreement with Novartis worth up to $2 billion. This development has reshaped the company's investment narrative, shifting focus from partnership-dependent revenue to a more balanced business model.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday on FDA Approval of First siRNA Therapy for FCS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Soars 5.08% Intraday on FDA Approval of First siRNA Therapy for FCS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-01 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals (ARWR) saw its stock price surge 5.08% during intraday trading on Monday, reflecting strong investor optimism following a significant regulatory milestone.</p><p>The rally was driven by the U.S. FDA's approval of REDEMPLO (plozasiran), Arrowhead's first siRNA therapy for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This approval marks a pivotal transition for the company into a commercial-stage entity, with REDEMPLO offering a quarterly self-administered treatment option at home.</p><p>The FDA nod not only validates Arrowhead's RNAi platform but also opens new revenue streams, supported by recent licensing and collaboration deals, including a global agreement with Novartis worth up to $2 billion. This development has reshaped the company's investment narrative, shifting focus from partnership-dependent revenue to a more balanced business model.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1194159638","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194159638","pubTimestamp":1764600383,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals (ARWR) saw its stock price surge 5.08% during intraday trading on Monday, reflecting strong investor optimism following a significant regulatory milestone.The rally was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"个股追踪|FDA批准FCS首款siRNA疗法Arrowhead Pharmaceuticals盘中大涨5.08%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (ARWR) saw its stock price surge 5.08% during intraday trading on Monday, reflecting strong investor optimism following a significant regulatory milestone.The rally was driven by the U.S. FDA's approval of REDEMPLO (plozasiran), Arrowhead's first siRNA therapy for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This approval marks a pivotal transition for the company into a commercial-stage entity, with REDEMPLO offering a quarterly self-administered treatment option at home.The FDA nod not only validates Arrowhead's RNAi platform but also opens new revenue streams, supported by recent licensing and collaboration deals, including a global agreement with Novartis worth up to $2 billion. This development has reshaped the company's investment narrative, shifting focus from partnership-dependent revenue to a more balanced business model.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194159638","isCrawlerRequest":true}